Not investment advice. Educational platform. See Disclaimer.
NASDAQ: BCAX
Bicara Therapeutics Inc. Common Stock
Healthcare | Biotechnology
No licensed closing price on file for BCAX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Bicara Therapeutics Inc. Common Stock (NASDAQ: BCAX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 02:12 UTC.
What Bicara Therapeutics Inc. Common Stock does
The company is a clinical-stage biopharmaceutical developer focused on bifunctional therapies for solid tumors. Its lead program, ficerafusp alfa, combines an EGFR-directed antibody with a TGF-beta ligand trap to target tumors while limiting systemic toxicity. The therapy is designed to enhance immune cell penetration into the tumor microenvironment by simultaneously blocking EGFR signaling and immunosuppressive TGF-beta pathways. Ficerafusp alfa is currently being evaluated in head and neck squamous cell carcinoma in combination with pembrolizumab, with a pivotal Phase 2/3 trial ongoing.
Summarized from Bicara Therapeutics Inc. Common Stock’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗